Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
Elife
|
April 3, 2020
Functionally heterogeneous human satellite cells identified by single cell RNA sequencing
Emilie Barruet, Steven M Garcia, Katharine Striedinger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 3, 2012
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib
Zhengping Wang, Jinfu Yang, Christopher Kirk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
Melissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Radiology and Oncology
|
December 12, 2022
Quantifying the changes in the tumour vascular micro-environment in spinal metastases treated with stereotactic body radiotherapy - a single arm prospective study
Balamurugan Vellayappan, Dennis Cheong, Salil Singbal, et al.
Plos One
|
February 27, 2015
Aberrant lymphatic endothelial progenitors in lymphatic malformation development
June K Wu, Christopher Kitajewski, Maia Reiley, et al.
Acta Dermato-Venereologica
|
March 31, 2011
Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa
Noor Almaani, Lu Liu, Patricia J C Dopping-Hepenstal, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 2, 2022
Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report
Moreno Perugini, Tricia J Johnson, Tania Maria Beume, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma
Sundar Jagannath, Ravi Vij, A Keith Stewart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 17, 2020
Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre
Gloria Hj Chan, Yong Xiang Gwee, Jia Li Low, et al.
Cancers
|
April 30, 2021
Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri
Alvin Wong, Balamurugan Vellayappan, Lenith Cheng, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
Elife
|
April 3, 2020
Functionally heterogeneous human satellite cells identified by single cell RNA sequencing
Emilie Barruet, Steven M Garcia, Katharine Striedinger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 3, 2012
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib
Zhengping Wang, Jinfu Yang, Christopher Kirk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
Melissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Radiology and Oncology
|
December 12, 2022
Quantifying the changes in the tumour vascular micro-environment in spinal metastases treated with stereotactic body radiotherapy - a single arm prospective study
Balamurugan Vellayappan, Dennis Cheong, Salil Singbal, et al.
Plos One
|
February 27, 2015
Aberrant lymphatic endothelial progenitors in lymphatic malformation development
June K Wu, Christopher Kitajewski, Maia Reiley, et al.
Acta Dermato-Venereologica
|
March 31, 2011
Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa
Noor Almaani, Lu Liu, Patricia J C Dopping-Hepenstal, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 2, 2022
Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report
Moreno Perugini, Tricia J Johnson, Tania Maria Beume, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma
Sundar Jagannath, Ravi Vij, A Keith Stewart, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 17, 2020
Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre
Gloria Hj Chan, Yong Xiang Gwee, Jia Li Low, et al.
Cancers
|
April 30, 2021
Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri
Alvin Wong, Balamurugan Vellayappan, Lenith Cheng, et al.
Page
of 9